Figure S8 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

SALL4 induction in cancer cell by 5-azacytidine modulates SALL4-TCR T cells activation. (A) Expression of SALL4 detected by qRT-PCR (top) and Western blotting (bottom) (Sall4 Antibody (G-3): sc-166033 Santa Cruz) for MDA-MB231 treated with 5-azacytidine (5-aza) (2µM) for 72h and 6 days. (B) Degranulation (CD107a) stainings assessed by flow cytometry comparing Mock and SALL4-TCR T cells for their SALL4 reactivity upon coculture with MDA-MB231 treated 72h and 6 Days with 5-Aza. T cells were cocultured for 5h at E:T ratio 1:50 for n=3 different HDs, mean ±SEM. Anti-HLA-A2 (BB7.2) were used for specific reactivity controls. Statistics were calculated using ANOVA test, *p